儿童急性T淋巴细胞白血病微小残留病研究现状及展望  

Current situation and prospect of minimal residual disease in pediatric T cell acute lymphoblastic leukemia

作　　者：牛凤凤 高超[1] Niu Fengfeng;Gao Chao(Department of Clinical Laboratory Center,Beijing Key Laboratory of Pediatric Hematology Oncology,Key Laboratory of Major Diseases in Children Ministry of Education,Beijing Children’s Hospital Capital Medical University,National Center for Children’s Health,Beijing 100045,China)

机构地区：[1]国家儿童医学中心、首都医科大学附属北京儿童医院检验中心,儿童血液病与肿瘤分子分型北京市重点实验室,儿科重大疾病研究教育部重点实验室,北京100045

出　　处：《中华血液学杂志》2025年第1期97-102,共6页Chinese Journal of Hematology

基　　金：国家自然科学基金(82170150);北京市自然科学基金(7192066)。

摘　　要：儿童急性T淋巴细胞白血病(T-ALL)因其高侵袭性和治疗复杂性而备受关注。近年来,随着医疗技术的进步和研究的深入,儿童T-ALL的治疗效果已得到显著提升。然而,微小残留病(MRD)的存在仍然是影响儿童T-ALL预后的重要因素。随着检测方法的不断发展,目前定量PCR、多参数流式细胞术和高通量测序技术的临床应用,已经能够对MRD进行精确地检测,从而实现患者个体化的精准治疗。本文旨在综述当前儿童T-ALL MRD的检测方法、多药联合化疗与造血干细胞移植中MRD监测与评估的临床意义,以及应用MRD衡量近期T-ALL中新疗法的反应性与有效性,并展望未来的研究方向和潜在的治疗策略。Pediatric T-cell acute lymphoblastic leukemia(T-ALL)has been attracted much attention due to its high aggressiveness and complexity of treatment.Recently,with the development of technology and clinical research,the curative effect of T-ALL in children has been significantly improved.However,the presence of minimal residual disease(MRD)is still a key factor affecting the outcomes of children with T-ALL.With the continuous development of detection methods,the clinical applications of real-time quantitative PCR,multi-parameter flow cytometry,and high-throughput sequencing technology,MRD can be detected accurately to achieve personalized and precise treatment for each patient.The purpose of this article is to review the current detection methods of MRD in T-ALL,the clinical significance of MRD monitoring and evaluation in multi-agent combined chemotherapy and hematopoietic stem cell transplantation,and applying MRD to measure the responsiveness and effectiveness of new therapies in recent T-ALLs.Research directions and potential treatment strategies in the near future were also proposed.

关 键 词：微小残留病 急性T淋巴细胞白血病 造血干细胞移植 多参数流式细胞术 精准治疗 展望未来 高通量测序技术 定量PCR 

分 类 号：R73[医药卫生—肿瘤]